CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis
RIO
1.5600
The Fort Worth Press - CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis
USD
-
AED 3.672501
AFN 63.526725
ALL 81.813592
AMD 370.44014
ANG 1.789884
AOA 917.999874
ARS 1397.970203
AUD 1.390396
AWG 1.8025
AZN 1.698617
BAM 1.673763
BBD 2.014848
BDT 122.744486
BGN 1.668102
BHD 0.378259
BIF 2976.953556
BMD 1
BND 1.277439
BOB 6.912222
BRL 4.942304
BSD 1.000406
BTN 95.268333
BWP 13.595091
BYN 2.832032
BYR 19600
BZD 2.011938
CAD 1.36142
CDF 2316.000493
CHF 0.781705
CLF 0.023071
CLP 908.020232
CNY 6.83025
CNH 6.827645
COP 3729.76
CRC 455.103656
CUC 1
CUP 26.5
CVE 94.363762
CZK 20.8327
DJF 178.141394
DKK 6.38328
DOP 59.605058
DZD 132.430042
EGP 53.707031
ERN 15
ETB 157.299296
EUR 0.85423
FJD 2.19545
FKP 0.738858
GBP 0.737155
GEL 2.684969
GGP 0.738858
GHS 11.214281
GIP 0.738858
GMD 73.516238
GNF 8779.444171
GTQ 7.636122
GYD 209.292176
HKD 7.83625
HNL 26.592098
HRK 6.436505
HTG 130.92574
HUF 308.760086
IDR 17394.7
ILS 2.939602
IMP 0.738858
INR 95.08205
IQD 1310.455489
IRR 1315000.000274
ISK 122.319935
JEP 0.738858
JMD 157.422027
JOD 0.708997
JPY 157.654028
KES 129.212585
KGS 87.420506
KHR 4012.802629
KMF 420.495892
KPW 900.003193
KRW 1468.325013
KWD 0.30805
KYD 0.833626
KZT 464.848397
LAK 21968.14747
LBP 89583.7434
LKR 320.121521
LRD 183.567107
LSL 16.741448
LTL 2.95274
LVL 0.60489
LYD 6.346517
MAD 9.245917
MDL 17.266433
MGA 4166.844956
MKD 52.680605
MMK 2099.706641
MNT 3578.607048
MOP 8.074899
MRU 39.944374
MUR 46.950245
MVR 15.454967
MWK 1734.687765
MXN 17.39417
MYR 3.962497
MZN 63.909766
NAD 16.741734
NGN 1368.129891
NIO 36.815644
NOK 9.25275
NPR 152.429814
NZD 1.695505
OMR 0.384485
PAB 1.000419
PEN 3.507156
PGK 4.350003
PHP 61.477989
PKR 278.776321
PLN 3.62844
PYG 6061.565584
QAR 3.656451
RON 4.475597
RSD 100.250691
RUB 75.448038
RWF 1462.717478
SAR 3.752423
SBD 8.025868
SCR 13.628303
SDG 600.502648
SEK 9.247415
SGD 1.274989
SHP 0.746601
SLE 24.649739
SLL 20969.496166
SOS 571.753772
SRD 37.477027
STD 20697.981008
STN 20.966603
SVC 8.752915
SYP 110.530725
SZL 16.738482
THB 32.526041
TJS 9.353536
TMT 3.505
TND 2.916547
TOP 2.40776
TRY 45.219905
TTD 6.781199
TWD 31.569503
TZS 2602.504135
UAH 43.963252
UGX 3776.555915
UYU 40.282241
UZS 12039.109133
VES 488.94275
VND 26323
VUV 118.524529
WST 2.715931
XAF 561.361905
XAG 0.013559
XAU 0.000218
XCD 2.70255
XCG 1.802894
XDR 0.697635
XOF 561.361905
XPF 102.06029
YER 238.624996
ZAR 16.66126
ZMK 9001.200338
ZMW 18.882166
ZWL 321.999592
- PSG 'not here to defend' against Bayern, says Luis Enrique
- Trump says he works out 'one minute a day' as he restores fitness award
- Russia hits Ukraine with deadly strikes as Zelensky denounces Moscow's 'cynicism'
- EU urges US to stick to tariff deal terms
- Hantavirus on the Hondius: what we know
- Rahm eligible for Ryder Cup after deal with European Tour
- Stocks rise, oil falls as traders eye earnings, US-Iran ceasefire
- Bayern's Kompany channels 'inner tranquility' before PSG showdown
- Colombian mine explosion kills nine
- Matthews latest England World Cup-winner out of Women's Six Nations
CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis
CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative therapies for high incidence immuno-dermatological disorders, today announced the initiation of a Phase 2b dose-ranging trial for its CGB-500 product. This topical JAK inhibitor ointment, developed using CAGE Bio's proprietary ionic liquid technology, represents a potential breakthrough for low body surface area (BSA), moderate to severe atopic dermatitis (AD) condition.
CGB-500 delivers medicine directly through the skin, combining high efficacy with minimal systemic exposure. Results from the 2024 Phase 2a trial showed efficacy comparable to biologics, outperforming current best-in-class topical treatments while maintaining a significantly lower side-effect profile. Specifically, CGB-500 had an 8-week treatment success of 95% (IGA score of "0" or "1" and > 2 grade improvement ).
This larger Phase 2b trial (n=180) will focus on optimizing dosing regimens and further assessing the safety and efficacy of CGB-500. This pivotal step underscores CAGE Bio's commitment to addressing the unmet needs of patients with moderate to severe AD and low body surface area (BSA) involvement, where treatment speed and efficacy must be balanced with the cost of systemic exposure and side effects.
"CGB-500 offers a promising solution for patients seeking rapid and effective localized relief potentially avoiding systemic therapies and their associated side-effects" said Dr. Justin Ko MD, a board-certified dermatologist in San Francisco Bay Area.
"Our ionic liquid platform continues to demonstrate its potential in enabling highly effective and targeted topical therapies. With the Phase 2b trial now underway, we are one step closer to transforming how atopic dermatitis is treated," said Nitin Joshi, Ph.D., CEO of CAGE Bio.
Atopic dermatitis is a chronic inflammatory skin condition affecting millions globally. Patients with highly localized, moderate to severe symptoms face limited treatment options. CGB-500 seeks to fill this gap, offering a high efficacy alternative with dramatically lower systemic exposure.
CAGE Bio remains committed to advancing clinical programs that deliver transformative therapies (efficacy of a biologic with safety of a topical ) for immuno-dermatological disorders.
About CAGE Bio
CAGE Bio is a clinical-stage biotechnology company developing innovative localized therapies for immune-mediated dermatological conditions. Its proprietary ionic liquid technology ensures effective drug delivery to target areas with minimal systemic exposure, improving patient outcomes.
Phone: +1 (650) 996-1845
email. [email protected]
SOURCE: CAGE Bio Inc.
D.Ford--TFWP
